In a report released yesterday, Steven Halper from Cantor Fitzgerald reiterated a Buy rating on Omnicell (OMCL), with a price target of $80. The company’s shares closed yesterday at $65.15.
Halper wrote:
“. We reiterate our Overweight rating on OMCL shares and maintain our 12-month price target of $80. After the close on the company reported 4Q18 results and provided better-than-expected 2019 guidance. Revenue was below our estimate. Non-GAAP EPS were nicely above and grew 30% y/y. The positive performance in the quarter appears to have been driven by completed XT implementations and strong performance of the XR2 and IVX Workflow products. The company’s profitability is improving due to the increasing number of platform deals. Importantly, record bookings in the quarter (+26% y/ y) benefited from earlier-than-expected timing of orders. OMCL also issued 2019 guidance that implies annual top-line growth of about 13%.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 19.7% and a 65.7% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Evolent Health.
Omnicell has an analyst consensus of Moderate Buy, with a price target consensus of $83.
See today’s analyst top recommended stocks >>
The company has a one-year high of $79.48 and a one-year low of $39.75. Currently, Omnicell has an average volume of 321.4K.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of automation and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.
